There are two strategies to consider for stopping atropine treatment.
Individual interventions may not result in the expected efficacy.
Presently, only atropine, pirenzepine, and 7-methylxanthine are shown to reduce myopia progression in human trials.
The researchers concluded that topical low-dose atropine appears to be safe and effective in a cohort of European schoolchildren.
A summary of the LAMP Study results
Axial elongation rate is faster in younger children undergoing ortho-k treatment.
When should one start atropine treatment for myopes?